Drugs / RD06-04
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06986018 | Jun → Dec 2025 overdue | anti-neutrophil cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myopathy | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06549296 | Sep 2024 → Aug 2026 | Sjogren syndrome, anti-neutrophil antibody associated vasculitis, idiopathic inflammatory myopathy, systemic lupus erythematosus +1 | Nanjing Bioheng Biotech Co., Ltd. | Suspended | No outcome recorded |
| Phase 0 | NCT06548620 | Aug 2024 → Aug 2026 | anti-neutrophil cytoplasmic antibody-associated vasculitis, multiple sclerosis, neuromyelitis optica, systemic lupus erythematosus +1 | Nanjing Bioheng Biotech Co., Ltd. | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06310811 | Mar 2024 → Dec 2026 | — | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Suspended | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RD06-04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06310811 ↗ |
| Modality | Cell therapy | “CAR T Cells” NCT06548620 ↗ |
| Route | Intravenous | “administered intravenously” NCT06986018 ↗ |
| Target | CD19 | “CD19-targeted CAR-T Cell Injection” NCT06548620 ↗ |